BioSpace News Archive

Illumina, Inc. announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

Salarius Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that the company is participating in Biotech Showcase Digital and BIO @ JPM. Both events will be held virtually and are scheduled alongside the J.P. Morgan 39th Annual Healthcare Conference 2021.

Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, announced that the company is participating in Biotech Showcase Digital and H.C. Wainwright BioConnect.

SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the closing of its previously announced underwritten public offering of common stock, pre-funded warrants and warrants.

Quanta, Inc. (OTCPK:QNTA), today announced that it entered into a Securities Exchange Agreement in order to acquire 51% of Medolife Rx, Inc., a Wyoming corporation(“Medolife Rx”) in exchange for the issuance of newly created Preferred Stock, which upon closing,

Dr. Reddy’s Laboratories Ltd., Appili Therapeutics and Global Response Aid FZCO announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for REEQONUS™ Tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.

Ultimovacs ASA, announced the initiation of FOCUS, a Phase II randomized clinical trial that will evaluate the Company’s proprietary universal cancer vaccine, UV1, in 75 patients with recurrent or metastatic head and neck cancer who will be treated with standard of care therapy pembrolizumab.

Cold Spring Harbor Laboratory scientists have discovered a gene-regulating snippet of RNA that may contribute to the spread of many breast cancers.

Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that its licensee, UNITY Biotechnology, has dosed the first patient in a Phase I clinical study of drug candidate UBX1325 in patients with diabetic macular edema.

DaVita Kidney Care announced that more than 100,000 DaVita patients have received a kidney transplant since 2000.